The global obesity epidemic continues to challenge medicine, but a new class of hormones may redefine what’s possible for weight loss.
At Leva Medical in Queens, NY, our patients have seen remarkable results with GLP-1 medications like semaglutide and tirzepatide.
Now, researchers are eyeing a powerful next-generation therapy: Cagrilintide obesity treatment, an amylin analog that works synergistically with GLP-1 agonists for even greater results.
This article explores what cagrilintide is, how it works, and why experts believe it could reshape obesity care in the coming decade.